Comparison of Mirtazapine and Olanzapine on Nausea and Vomiting following Anthracycline-Cyclophosphamide Chemotherapy Regimen in Patients with Breast Cancer

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 54 人开始时间: 待定最近更新: 2020年2月24日

试验速览

暂无简介。

•Patients with Newly Diagnosed Breast Cancer
•Receiving Anthracycline-Cyclophosphamide Chemotherapy Regimen in the adjuvant Setting for at least Two consecutive Cycles
•Patients aged 18 to 65
•Written Informed Consent
•The Patient is able to read and understand the Questionnaires used in the Study

•A History of Allergy to Mirtazapine or Olanzapine
•Patient with History of Dementia, peptic Ulcer, myocardial Infarction, Seizure, Arrhythmia, Glaucoma, and bipolar Disorder
•Concomitant use of any Drug with Class X and D Interaction with the Drugs studied
•Increased basal Creatinine (SrCr = 1.5) or AST or ALT = 3ULN
•Brain Metastasis or Metastases with gastrointestinal Obstruction
•Having Nausea and Vomiting within 24 hours prior to Chemotherapy
•Patients with Disabilities taking oral Medications
•On chronic antiemetic Therapy (e.g.Metoclopramide); on long Term use of systemic Steroids prior to Chemotherapy
•Uncontrolled Diabetes
•The Patient has a History of any Illness that, in the Opinion of the Investigator, might confound the Results of the Study or pros unwarranted Risk

发起方